Biofrontera Inc (BFRI) Stock Price, Quote & News

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatmen...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 245 1325

Website: www.biofrontera-us.com

Address:

120 Presidential Way, Suite 330, Woburn, United States

MrTicker Dec. 4 at 8:51 PM

$BFRI solid news, low volume day.. keep an eye on this after hours for a possible run

0 · Reply

prismmarketview Dec. 4 at 5:19 PM

Biofrontera ( $BFRI) completes Phase 1 PK study for Ameluz gel on neck, trunk, and extremities, paving way for sNDA in summer 2026 to expand actinic keratosis treatment beyond face/scalp. https://prismmarketview.com/biofrontera-completes-phase-1-pk-study-for-ameluz-targeting-a-broader-actinic-keratosis-market/

0 · Reply

m2139m Dec. 4 at 4:29 PM

$BFRI SLEEPING 😴🥱

0 · Reply

MrTicker Dec. 4 at 2:08 PM

$BFRI Biofrontera Completes Final Patient Visit In Phase 1 Pharmacokinetic Study Of Ameluz Gel, 10%, For Treatment Of Mild To Moderate Actinic Keratoses On Neck, Trunk And Extremities BENZINGA 8:07 AM ET 12/4/2025

0 · Reply

MrTicker Dec. 4 at 2:01 PM

$BFRI Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities GLOBENEWSWIRE 8:00 AM ET 12/4/2025

0 · Reply

MrTicker Dec. 2 at 11:14 PM

$BFRI already tested and broke the 10 day high of .98 then pulled back, 30 day at $1.32 ,

1 · Reply

MrTicker Dec. 2 at 11:12 PM

$BFRI doubled todays volume in 5 min, after hours, 1 hr 45 min of after hrs trading today.. lets see how strong this runs.. long over due.

1 · Reply

MrTicker Dec. 2 at 11:09 PM

$BFRI tapped $1, on the move

0 · Reply

dbr_island Dec. 2 at 11:08 PM

🚨EPOW🚨NEWS JUST OUT AH🚨 PT: $2 🎯✅ $BFRI let’s do this

0 · Reply

MrTicker Dec. 2 at 11:05 PM

$BFRI seeing some after hours volume picking up on sNDA filing news earlier today

0 · Reply

Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Dec 2, 2025, 8:45 AM EST - 13 days ago

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

Nov 13, 2025, 11:51 AM EST - 4 weeks ago

Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 8:15 AM EST - 4 weeks ago

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

Nov 7, 2025, 8:00 AM EST - 5 weeks ago

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Nov 6, 2025, 4:01 PM EST - 5 weeks ago

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

Oct 23, 2025, 8:45 AM EDT - 7 weeks ago

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Sep 26, 2025, 9:15 AM EDT - 2 months ago

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 23, 2025, 9:20 AM EDT - 2 months ago

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

Sep 16, 2025, 10:30 AM EDT - 3 months ago

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

Aug 25, 2025, 8:25 AM EDT - 4 months ago

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Aug 14, 2025, 12:36 PM EDT - 4 months ago

Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript

Aug 13, 2025, 5:20 PM EDT - 4 months ago

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 11, 2025, 4:25 PM EDT - 4 months ago

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Aug 4, 2025, 2:00 PM EDT - 4 months ago

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Jun 30, 2025, 8:00 AM EDT - 6 months ago

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Jun 11, 2025, 3:00 PM EDT - 6 months ago

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Jun 3, 2025, 2:30 PM EDT - 6 months ago

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

May 16, 2025, 3:36 PM EDT - 7 months ago

Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript

May 15, 2025, 5:09 PM EDT - 7 months ago

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

May 15, 2025, 12:17 PM EDT - 7 months ago

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

May 6, 2025, 12:45 PM EDT - 7 months ago

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

May 1, 2025, 2:38 PM EDT - 8 months ago

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Mar 21, 2025, 11:20 AM EDT - 9 months ago

Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript

Mar 21, 2025, 8:00 AM EDT - 9 months ago

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Mar 18, 2025, 9:30 AM EDT - 9 months ago

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Mar 11, 2025, 10:00 AM EDT - 9 months ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Jan 8, 2025, 9:50 AM EST - 1 year ago

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Dec 23, 2024, 9:30 AM EST - 1 year ago

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Dec 3, 2024, 11:00 AM EST - 1 year ago

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 22, 2024, 9:10 AM EST - 1 year ago

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Nov 14, 2024, 3:02 PM EST - 1 year ago

Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 5:15 PM EST - 1 year ago

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Nov 1, 2024, 11:55 AM EDT - 1 year ago

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Oct 31, 2024, 10:32 AM EDT - 1 year ago

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 14, 2024, 10:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 7, 2024, 8:45 AM EDT - 1 year ago

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 15, 2024, 1:34 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 9, 2024, 10:00 AM EDT - 1 year ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

May 16, 2024, 2:44 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:45 PM EDT - 1 year ago

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

May 6, 2024, 10:30 AM EDT - 1 year ago

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

May 3, 2024, 8:50 AM EDT - 1 year ago

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Mar 26, 2024, 4:30 PM EDT - 1 year ago

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Mar 18, 2024, 12:13 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

Mar 15, 2024, 8:25 PM EDT - 1 year ago

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 15, 2024, 6:10 PM EDT - 1 year ago

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

MrTicker Dec. 4 at 8:51 PM

$BFRI solid news, low volume day.. keep an eye on this after hours for a possible run

0 · Reply

prismmarketview Dec. 4 at 5:19 PM

0 · Reply

m2139m Dec. 4 at 4:29 PM

$BFRI SLEEPING 😴🥱

0 · Reply

MrTicker Dec. 4 at 2:08 PM

0 · Reply

MrTicker Dec. 4 at 2:01 PM

$BFRI Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities GLOBENEWSWIRE 8:00 AM ET 12/4/2025

0 · Reply

MrTicker Dec. 2 at 11:14 PM

$BFRI already tested and broke the 10 day high of .98 then pulled back, 30 day at $1.32 ,

1 · Reply

MrTicker Dec. 2 at 11:12 PM

$BFRI doubled todays volume in 5 min, after hours, 1 hr 45 min of after hrs trading today.. lets see how strong this runs.. long over due.

1 · Reply

MrTicker Dec. 2 at 11:09 PM

$BFRI tapped $1, on the move

0 · Reply

dbr_island Dec. 2 at 11:08 PM

🚨EPOW🚨NEWS JUST OUT AH🚨 PT: $2 🎯✅ $BFRI let’s do this

0 · Reply

MrTicker Dec. 2 at 11:05 PM

$BFRI seeing some after hours volume picking up on sNDA filing news earlier today

0 · Reply

JohnTrack Dec. 2 at 4:47 PM

$BFRI sNDA filed, nice move! https://www.rapidticker.com/news/bfri-biofrontera-inc-announces-filing-of-2c8311

1 · Reply

MrTicker Dec. 2 at 2:22 PM

$BFRI solid PR, news hasn't set in yet.. it will run.. keep an eye on it

2 · Reply

Rybod30 Dec. 2 at 2:07 PM

$BFRI Red on those results, I’m missing something here obviously😬🤷‍♂️

0 · Reply

Rybod30 Dec. 2 at 1:58 PM

$BFRI What am I missing here, news is great, company numbers not horrible, float low🤷‍♂️😬..

0 · Reply

Timothyb Dec. 2 at 1:53 PM

$BFRI finally 😅

0 · Reply

MrTicker Dec. 2 at 1:50 PM

$BFRI BRIEF-Biofrontera Inc. Announces Filing Of Supplemental New Drug Application REUTERS 7:49 AM ET 12/2/2025

0 · Reply

MrTicker Dec. 2 at 1:49 PM

$BFRI Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes BENZINGA 7:48 AM ET 12/2/2025

0 · Reply

MrTicker Dec. 2 at 1:48 PM

$BFRI WOBURN, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc.(BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the submission of an sNDA to the FDA, seeking approval of Ameluz®-PDT for the treatment of sBCC.

0 · Reply

MrTicker Dec. 2 at 1:47 PM

$BFRI sNDA filing.. solid news, due for a break out.. keep an eye on this

0 · Reply

MrTicker Dec. 2 at 1:46 PM

$BFRI Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT GLOBENEWSWIRE 7:45 AM ET 12/2/2025

0 · Reply

Blutan Nov. 24 at 7:28 PM

$BFRI Professor Dr. Lübbert aims to bring “his company” into profitability in the first quarter of next year, for his own benefit. The success of Biofrontera Inc. is therefore quite likely. Otherwise, numerous lawsuits would very likely follow.

1 · Reply

ivo98 Nov. 20 at 7:56 PM

$BFRI the numbers are bad. 🤭 Below $0.8 🤗

0 · Reply

Market Cap	9.46M
Revenue (ttm)	37.32M
Net Income (ttm)	-17.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-47.59%
Debt to Equity Ratio	-1.73

Volume	62,800
Avg Vol	138,884
Day's Range	N/A - N/A
Shares Out	11.65M
Stochastic %K	19%
Beta	0.57
Analysts	Strong Sell
Price Target	$6.00